Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Arjo, Audiocast, Q4'25

By Inderes1/30/2026, 12:00 PM
Arjo

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Andréas Elgaard
00:02 - 06:58

Thank you very much. Everybody that has called in to this Q4 year-end report 2025. My name is Andréas Elgaard, and with me today I have Christofer Carlsson, and I will start the meeting and then we'll hand over to Christofer when we come into the financial figures. And we'll do this together. So before we begin, I've started now in Arjo since three plus weeks back. So I'm still new at work, and I'm super excited to lead this first call and also to share a little bit with you guys what I'm experiencing as a new person, discovering Arjo. And I thought also that maybe it's a good idea that it could be some new newcomers to this call who are interested in getting to know Arjo a little bit. So just very, very briefly. We are experts in improving mobility in acute care and long-term care settings, and our products truly make a difference when people are at their most vulnerable. They provide safety, dignity, and integrity to patients. And they also provide good working conditions for the caregivers. And of course, they deliver value to the clinics and to the institutions where they are in use. Arjo is founded in the south of Sweden in Eslöv by Arne Johansson. That's also where the name comes from. It has a long tradition, leading up to where we are today, an 11 billion company with almost 7000 co-workers and with active sales in 100 plus countries. I think we can take the next slide. And when you're new, of course, you discover the company, and I discover ARJO through all the products and our business, but mainly I discover it through the lens of all of our people. And we have a very, I would say, rich company in terms of diversity. We have many businesses, we are active across many countries, and we have many versions of Arjo out there. And it's really the people that represent these, these different versions. So a lot of diversity across Arjo. We're not always using that to our benefit to drive maybe best practice or learn from successes or failures. But there is one thing that we have in common across Arjo, and it was a big reason why I wanted to join as well: we are all connected. And we are, I would say, really passionate about the purpose. And it is the purpose of doing good, to be there when patients are at their most vulnerable situations and provide products that truly help the care situation. I already said it, but integrity, dignity, and safety are super important when you are in this position. And also to provide that in a safe way. So it is something that is truly a superpower in Arjo and something we will build on for the future. So let's talk about Q4. So, first of all, I would say that we had stable demand throughout the quarter. And then towards the end of the quarter, we did not see the development we would have wished, as we have been challenged by, of course, currency and tariffs. We have also been challenged by price pressure in parts of our markets and by the product mix, resulting in slightly higher growth in markets with lower margins compared to those with higher margins. But overall, healthy organic growth, very strong cash flow in the quarter. So we almost hit our yearly cash conversion targets, but really strong in the quarter. And of course, we had hoped for more when it comes to the gross margin and maybe some of our cost control; we can look a little bit into the full year. So when we zoom out and look at the full year, we see a growth figure that is within the range that we have promised. And we can see that we deliver this despite being challenged, I would say mainly in UK, where we all know that the market in UK and the political situation, the struggles in the healthcare system, UK is also something that hits Arjo and has been a red thread throughout the year. That is impacting our performance, I would say. And then the headwinds in terms of tariffs and currency, together with price pressure in parts of our range, and the mix is challenging our profitability and margin. Overall, regarding our EBITDA, we had expected a little more from the quarter. But if you look at the full year, given the adjustments that have been throughout the year, some of the write-offs, this is the level that we landed on. As I mentioned previously, thanks to the strong performance in Q4, we managed to almost come up in line with our target of 80% cash conversion. We are just south of that. And then, very important to highlight, is that we propose to stick to the same level of dividend that we had last year, and the Board is recommending to the AGM a dividend of 956. Just very briefly on North America and global sales, the two segments that we have, you can see that the quarter in North America was slowed down a little bit. But looking at the full year, it was quite strong growth. And looking then at global sales, we had a reverse trend where we had a stronger finish and a full year that was more, I would say, stable. It's important to note that some of the more emerging markets in what we call the rest of the world have high growth, and these are also areas where we have slightly different profitability and gross profit levels, impacting the overall gross profit by approximately 1%. And then, US tariffs, FX (currency) effects, and similar factors are also relevant. is approximately another percent. When you look at us from the outside and compare with last year. And by that, I think it's time to hand over to Christofer. Towards the end of the quarter, we saw maybe not the development that we would have wished; we have been challenged by currency and tariffs. All right. Yes.

Christofer Carlsson
06:58 - 12:51

My name is Christofer Carlsson. I'm the CFO of Arjo. As Andreas mentioned, profitability was a challenge in the quarter. Our gross margin came in at 42.1% compared to last year's 44.7%. We continue to have headwinds from currency and US tariffs, representing around one percentage point of the drop. In addition, one percentage point can be explained by the unfavorable geographic and product mix due to higher sales in global markets with higher volumes of medical beds. On top of this, this year's flu season pressured our rental margins, and we also saw an impact from continued price pressure in the DVT business in the US in the quarter. Meanwhile, we had a good momentum and margin development in the rental business. This positive trend was especially evident in continental Europe, particularly in France, Germany, and Italy, during the quarter. However, the market condition in the UK continued to be a challenge, and the 11 percentage point drop in UK sales consequently had a negative impact on the gross profit and offset the positive effect from continental Europe. All in all, a disappointing finish to the year from a gross margin perspective where we did not have a seasonal uptick that we usually see due to a number of headwinds. This good momentum was particularly notable in Continental Europe, especially France, Germany, and Italy, in the quarter. Adjusted EBIT in Q4 came in at 249 million versus 375 million. The main driver is the drop in gross profit and an OPEX increase of 23 million. We had a negative effect from the revaluation of accounts receivable and accounts payable of 3 million in the quarter, booked under other operating expenses, which was a positive 19 million in the same quarter last year, resulting in a delta of 22 million. Year over year, total FX impact on adjusted EBIT amounts to 73 million in the quarter. The EBIT margin decreased to 8.9% versus 12.5% last year. On the OpEx side, the increase in the quarter is mainly driven by higher sales of capital sales in the US, resulting in higher GPO fees and sales commission. The organic OPEX increase was 1.9% in the quarter, which means that adjusted for the variable cost, we see a good traction from the cost efficiency initiatives implemented earlier this year. Adjusted EBITDA for the quarter was 526 million, versus 653 million in Q4 last year; the adjusted EBIT margin decreased with 3.2 percentage points versus last year. Restructuring costs came in at 68 million in the quarter, where 35 million is the write-off of capitalized IT costs related to an ongoing IT harmonization project. This initiative is expected to lead to annual savings of at least 30 million from 2028 and onwards. Another 30 million related to ongoing improvements in our global sales structure to improve the cost structure for the future. Next slide please. Operating cash flow continued to improve in the quarter, amounting to 600 million SEK. This was 121 million SEK higher year over year, primarily due to inventory reduction and receivable collection. The decrease in inventory is significant in the quarter, which helps to turn the full-year figure into a positive one. Our increased capital sales, together with the supply chain inventory reduction program, are now starting to show results. Working capital days decreased to 76, down from 82 in Q3, and it's good to see a continued positive trend here. The working capital improvement is also the driver for the improved operating cash flow of 600 million in the quarter. Consequently, cash conversion in the quarter was almost 120% compared to 82% last year. For the full year, we came in at 79%, which is in line with our target of 80% and an increase versus 2024. For reference, cash flow from investing activities was 172 million, compared to 191 million in Q4 24. The decrease is mainly due to 23 million lower investment in tangible assets. This quarter includes an investment of 90 million in a Dutch entity, Singlecare, which was announced in the Q3 report. Please next slide. The decrease in net debt this quarter is mainly due to the improved operating cash flow. Our financial net came in at -77 million SEK, which includes a non-cash flow impact of 35 million SEK. Negative revaluation of our holdings in Atlas, Phoenix, and Webplus. Adjusted for this revaluation of our financial assets, the financial net was -42 million and on par with last year. Our cash position remains strong. Net debt to adjusted EBITDA stayed flat versus Q3 this year and came in at 2.2. Our equity ratio stood at 49.8%, up from 49.5% in Q3, mainly due to the improved cash flow. With that, I will hand it back to you, Andreas.

Andréas Elgaard
12:52 - 16:41

Thanks, Christopher. So let's look ahead. How will we define our future direction? And I would like to say that there is always ongoing positive work in preparing for the future. During 2025, we launched the Maxi Move 5 that many customers think is really a game changer. We have just recently also launched the new hygiene solution, Symbliss, that has received a lot of positive acclaim so far. And we're going to continue to rejuvenate our offer and how we go to market going forward. But maybe just a few words on what it means to work on this. So we have a solid foundation to build on. We have a macroeconomic perspective. Economics, I would say, or trends that are incredibly positive for us, including people living longer and more people coming out of poverty. The need for care is growing faster than the population is growing and the GDP is growing. So, from a macro perspective, all things are positive. At the same time, we also know that many political systems and many healthcare systems are under pressure because it is difficult to keep up with the growing need of care. There are changes in how care is being distributed, administered, and given to patients. All of these things will create a more dynamic market in the future, and it's very important for Arjo to set our point of view on that. Part of our foundation is also that we have a very passionate team, dedicated and committed to the purpose of doing good for our patients and caregivers. So that said, there's also a lot of things that Arjo can do that is not about the macro, that is not about the patients, but that is about our own performance. And there's significant opportunity across ARJO to share best practice, learn by that, and implement going forward, using this to decide on the future in order to take out maybe cost and drive efficiency. So we can look at the next slide. So how do we realize our potential? Part of that is to know where we're going and setting a strategy, setting a direction. And we intend to present this back to the market in the second half of this year. The work has already started, and we will bring together leaders from all parts of ARJO. We are going to workshop with them and decide on where we want to go for the future, how we will get there, what to prioritize, what not to do, which markets to focus on, which parts of our product portfolio to put emphasis on, and if needed, acquire additional capability, additional market position, or maybe additional portfolio offering. And those things are all easier when you have clarity in your strategic direction. And I think that for ARJO, the last time we set a strategy was back in end of 2019. So we are due to create that clarity for ourselves and for all our shareholders. We, the only outlook that we give right now is, of course, the usual one, about 3 to 5%. And we are really looking forward to presenting our future direction. And with that, also, update the financial targets in the second half of 2026. So that's what you can expect from us during this year. And by that, I think we are at the Q&A.

Operator
16:43 - 17:02

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Sten Gustafson from ABG Sundal Collier. Please go ahead.

Sten Gustafson
17:03 - 17:30

And we are really looking forward to presenting our future direction. Good afternoon. A question on the quarter. You talked about a strong start. But then it slowed down. I was just wondering if you could clarify exactly what happened there, and also if that change in the market has continued into the beginning of 2026.

Andréas Elgaard
17:33 - 18:14

Thank you for your question. I would say no, that's not how to interpret it. I would say that it's more how we see the result developing across the quarter. So we don't see any trend shifts that we bring with us. We instead see that we expected more from the quarter. And I would say that, you know, you all know that when you close, when you close the books, there are some decisions that you need to take. And as you have seen, we have had a couple of write-offs or write-downs during the quarter. That of course, impacts the situation. So I would say that there's nothing to interpret concerning what to bring forward into 2026.

Sten Gustafson
18:16 - 18:17

And as you have seen, we have had a couple of write-offs or write-downs during the quarter. That's good.

Andréas Elgaard
18:17 - 18:19

Would you like to add something to that maybe.

Christofer Carlsson
18:19 - 18:29

No, it's always an uncertainty about the flu season that is impossible to predict. Exactly. Of course, how that will develop.

Andréas Elgaard
18:29 - 18:29

Yeah.

Christofer Carlsson
18:30 - 18:32

And it can go in both directions.

Sten Gustafson
18:35 - 18:52

So I would say that there's nothing to interpret regarding what will be carried forward into 2026. As you have seen, we have had a couple of write-offs or write-downs during the quarter. And then, specifically the UK, when do you expect that to improve, or do you expect it to improve near term, or is it too difficult to say today?

Andréas Elgaard
18:53 - 20:07

I would say that. There are two things here. One is, of course, what is going on in the UK, within the NHS and the UK healthcare system. That's one part of it. And of course we can, we can try to contribute with as much value as we can and to be a good partner to our customers and NHS in particular. So that's one part. Then it's also about our own performance and what are we doing in this situation. And we've had a lot of actions throughout 2025 to improve our efficiency and productivity. So we have done several things throughout the year that we expect will have effects if it's enough or not, or what will happen in the bigger picture around NHS. That's another topic. Most of you that follow this sector know that the UK is really troubled. The pressure on the healthcare system is very high. And there have been some fundamental challenges that still remain going forward. This is a top priority for all political parties. So we also believe that there is a lot of interest in solving this for the benefit of the people across UK.

Sten Gustafson
20:09 - 20:12

Okay. Thank you very much. I'll get back into the queue.

Operator
20:16 - 20:19

The next question comes from Matthias Vanston from CIB. Please go ahead.

Matthias Vanston
20:22 - 20:34

Hi. Thank you for taking my questions. First one is just a follow up on the UK. Did you say it was down 11% year on year in local currency in Q4?

Christofer Carlsson
20:35 - 20:39

Yes. That's correct. It's down 11% in the quarter.

Matthias Vanston
20:40 - 20:42

In local currency.

Christofer Carlsson
20:42 - 20:46

Yes. Organic. The delta is the 11% down.

Matthias Vanston
20:47 - 21:18

Thank you. Then, you talked about the gross margin development. It's quite a clear description. And you talked about the mix effect, both from a regional perspective and product perspective. So I'm just asking this mix effect that you saw in Q4. Is that likely to sustain here into the coming quarters, or are you seeing anything to reverse that trend near term?

Andréas Elgaard
21:21 - 22:56

Maybe if I try to start and then Christofer can correct my mistakes or add on flavor. No, no, I think it's. I don't think that you can draw any major conclusions like that, that it is now a sustained level. I think it's as always, it's a product mix question. It's a market mix question. Also, parts of our business are project-driven and tender-driven. And depending on how these projects or programs land, you get different mixes that will vary naturally between different quarters. So, that's the natural flow. So we don't have that kind of super stable underlying trend. So that's one thing to bring with you. And then also, of course, as we said earlier, we expected a different pattern from the flu season in the US. And when you look at statistics and data, if you just look at the high level, you can see that the flu season looks to be more severe when we dig down in the areas where we have strong representation, especially Western US, the hospitalization is not as high as last year. And also in general, the flu seems to not cause as much hospitalization as previous years. But it's very early, and all data is not accessible. But we have seen that trend in our data. So I don't know if you want to add some flavor in terms of if this mix or this trend is moving forward, just on that point.

Christofer Carlsson
22:56 - 23:16

No, I said the medical business has a strong development in this quarter, but that is also very much a business. You know, depending on tenders and big shipments. It's not a continuous business in that sense. So it could be a different product mix in the next quarter for us.

Andréas Elgaard
23:17 - 23:24

When you equip a hospital, you do that once, then it takes a number of years before you get the chance to come with a big order again.

Matthias Vanston
23:27 - 23:56

Then I had a question on the ERP systems that will be replaced by a global system. So we don't have that kind of super stable underlying trend. Then I had a question on the ERP systems that will be replaced by a global system. And you said you will find savings of 30 MSEK from 2028 onwards. I'm looking to understand what this will cost you. Can you comment on the cost for this in 2026 and 27, and also how you're able to report it, if it's a non-recurring item or if it will be a drag on adjusted earnings metrics.

Christofer Carlsson
23:59 - 24:11

The vast majority of the cost for this implementation is actually capitalized because we own the product. So it's not a cloud solution.

Andréas Elgaard
24:14 - 24:39

And maybe to add some flavor, this has been ongoing for a couple of years in ARJO already. So we only have a few markets left to do this change. So it's not something that is new to us. It's something that has been ongoing for a couple of years. So we had a couple of go-lives during 2025 already. And, yeah.

Christofer Carlsson
24:40 - 25:10

We went live with Australia and New Zealand this year. And that was kind of the key point where, with the successful implementation in Australia and New Zealand, we decided to also go ahead for the rest of the countries. Otherwise, with a less positive outcome in Australia, we would probably have put on the brakes and reversed this project somehow. So this was the key decision point for taking this course as well.

Matthias Vanston
25:12 - 25:17

And that was the key point where, with the successful implementation in Australia and New Zealand, we decided to also go ahead for the rest of the countries. Otherwise, with a less positive outcome in Australia, we would probably have put the brakes on and reversed this project. Is it possible to say how much it has cost you already or with this?

Andréas Elgaard
25:17 - 25:35

No, we have not shared that. But I think the write-down is for the old system. Yes, this is important to us because we discontinue it before end of life. so. It's not so. It's not connected to the new.

Matthias Vanston
25:38 - 25:39

That was the key point where, with the successful implementation in Australia and New Zealand, we decided to also proceed for the rest of the countries. Otherwise, with a less positive outcome in Australia, we would probably have put on the brakes and reversed this project. That was a key point where, with the successful implementation in Australia and New Zealand, we decided to proceed with the rest of the countries; otherwise, with a less positive outcome in Australia, we would probably have put the brakes on and reversed this project.

Operator
25:44 - 25:48

The next question comes from Christopher Lilleberg from Carnegie. I agree, it started slowly, but while public statistics show it picked up a lot in the last three weeks of the fourth quarter, you didn't see that in your rental business then, correct?

Christopher Lilleberg
25:50 - 26:12

I think you have three questions. So take them one by one. First, what do you say about the flu hospitalization? I agree, it started slowly, but if you're looking at the public statistics, it picked up a lot in the last three weeks of the fourth quarter, but you didn't see that in your rental business then, correct?

Andréas Elgaard
26:13 - 26:47

Like we said before, we have seen that the flu season has been stronger or more severe than last year, but it is also distributed differently across the US. So in the States where we are strong, we have not had the same pattern of hospitalizations. And also we have seen a pattern that fewer patients are being hospitalized. Or they quickly get out of hospital versus before. So we don't see a 1 to 1 pattern as before.

Christopher Lilleberg
26:49 - 27:27

Were the disappointing sales for you in Q4 all flu-related? That makes sense. Then I wanted you to clarify what still seems like a pretty poor visibility for sales in North America. The message of the third quarter was that you had delayed deliveries. That was expected to pick up in Q4. So did you see this happen? Were the disappointing sales for you in Q4 all flu-related? That capital equipment sales were according to plan.

Christofer Carlsson
27:30 - 28:19

The vast majority is, of course, the flu season. But we also have seen fewer improvements in Canada, which had very strong comparison numbers. So they actually have a lower growth in the quarter versus the US. And to some extent, it didn't pick up at the end. Normally there are quite a lot of transactional sales. What we often see is that hospitals call the last week or the last two weeks when they know that they have X dollars remaining of the budget and they just need to purchase something before the year end. And that volume did not repeat from last year's all-time record transactional volume.

Christopher Lilleberg
28:20 - 28:22

Do you know why that was the case?

Christofer Carlsson
28:23 - 28:41

I think there are general budget constraints in the Canadian market. We do see some of the states being more and more restricted in their budgets. But that's the main reason, I think.

Christopher Lilleberg
28:43 - 29:01

That capital equipment sales were according to plan. And then my final question, you talked about the mix effect. That could of course vary a lot between quarters, but otherwise, is there anything you could do here short term to turn this negative margin trend?

Andréas Elgaard
29:04 - 30:25

From my point of view, being new now into the company, if I answer first and then Christofer can add on, I would say that Arjo has a lot of potential to drive efficiency. I would say both in cost and capital out. That's clear. We are going to work on that to do our own homework, so to say. Then also, I think that we need to look into parts of our business where market conditions have maybe changed a little bit or market dynamics have changed a little bit. We also need to update our commercial models and make sure that we share best practice in a more rapid way so we can be quicker to react. So there are always things that you can do on your own. Sometimes there's a lag in that, of course, because you don't know what is changing before it's happened. And then it takes some time to adjust. But there are always things that we can do on our own, and we intend to do that. And in the strategy work, there will be long-term initiatives that we want to pursue to build capability, expand our offering, or strengthen our market position; however, we also need to fund that journey to a large extent. We're going to do that. Also, I would say efficiency initiatives across the group.

Christopher Lilleberg
30:27 - 30:48

And you will start the strategy work. If you start this strategy work now, then you're going to present this in the second half of the year. It sounds that 2026 will be yet another lost year when it comes to margins for Arjo, or am I missing something here?

Andréas Elgaard
30:49 - 31:48

Yeah. There are always parts that require long-term direction, and for an organization to come together, that will take some time. But there are also plenty of quick wins that you can activate around procurement. And your own efficiency. So, I have worked a lot with change in the past, and I. I'm a firm believer in that. You have to transform yourself. You have to change, but you also have to perform while you do that. And you need to fund the journey to invest in capability, in products, or in M&A. Somehow you need to fund that journey. And you do that by driving efficiency in both capital and cost out of the company. So I think that you cannot say that you need to wait another year. I think we will be very, very focused on these also short-term actions.

Christopher Lilleberg
31:51 - 31:52

But there are also plenty of quick wins that you can activate around procurement. The first one is a follow-up on the last one around the strategy work that you will initiate in the spring.

Operator
31:56 - 32:01

The next question comes from Ludwig Gemunder from Handelsbanken. There are always parts that require direction and long-term commitment, and where the organization needs to come together, which will take some time.

Ludwig Gemunder
32:03 - 32:21

Good afternoon. I'm from Handelsbanken. Thanks for taking my questions. I have two, please. The first one is a follow up on the last one around the strategy work that you will initiate in the spring. I understand that you will do work in the meantime as well, but what should we expect regarding margins for the beginning of 2026?

Andréas Elgaard
32:22 - 33:13

We usually don't give any forecasts, and we will continue not to. The only outlook we give is how we believe sales will develop on the top line within the 3 to 5% interval. So beyond that, we will not share any outlook until we may have a reason to do that. So that's, and as I said before, we expect to come back and explain our view on the future. And also at that point, also potentially revise our financial targets. So we need to work this through before we communicate it. But we are going to be super focused on trying to drive efficiency before we present our future direction.

Ludwig Gemunder
33:16 - 33:44

Okay, I got it. And the second one is also a follow-up on the discussion. And the second one is also a follow-up on the discussion. That was around the flu season. I understand that hospitalization levels are lower in the parts of the US where you are most active. Could you say something about the sequential development or demand you're seeing from the flu season? Is it at the same levels so far in Q1 as you saw in Q4, or has it moved in any direction from the Q4 levels?

Andréas Elgaard
33:46 - 34:02

We're not reporting Q1 today, so we stay on Q4. So, what we have seen is that the flu this year resulted in fewer hospitalizations. That's what we've seen in Q4.

Ludwig Gemunder
34:04 - 34:07

Okay, I got it. Thanks for taking my questions.

Operator
34:11 - 34:15

The next question comes from Eric Castle from Danske Bank. Hi.

Eric Castle
34:17 - 34:39

Hi. First question on North America. If my modeling is decent, it looks like the rental business now is in organic decline over there. Could you potentially comment anything if that only has to do with the ICU rental part? Or if you're also seeing that for the more long-term contracts as well.

Christofer Carlsson
34:41 - 34:46

Now that is more from the short term perspective. And the flu season I would say.

Eric Castle
34:49 - 35:23

So, as I said before, we expect to come back and explain our view on the future. As I said before, we expect to come back and explain our view on the future. And then on DVT, that business has been under pressure for several years now. Cardinal started cutting back in 21. So how much additional pressure can you face there now? And can you talk a bit about the sort of current levels of sales and profits to some extent that you're seeing. And we should expect that pressure to continue now throughout 2026 as well. If there were any, say, pricing cuts now in Q4, that would sort of feed over into at least H1 of 26.

Andréas Elgaard
35:25 - 36:16

We will not talk about 2026, but what we can say is that there's fierce competition on the consumables in the VTE part of our business. And I think that Cardinal and others have pushed the prices down. We also believe that we are either at the bottom or close to the bottom of how far down you can go. And then you can say also that triggers the need for us to counter by looking at our business model, if it is set up for this level or if we need to do any adjustments, but we don't expect the decline to continue in the same pace that it has the last couple of years. Is that correct, Christopher?

Christofer Carlsson
36:16 - 36:21

Yes. So the vast majority of our business is on the new price level.

Eric Castle
36:24 - 36:59

How much are you actually able to slim the organization from this point? Good. In the UK, are you seeing continued rental pressures for more and more contracts being lost, or is this still an effect of those initial what was it, 5 or 7 contracts that you lost earlier in 25 that in a way should be out of comps soon and also in UK? And then, in the UK, are you seeing continued rental pressures for more and more contracts being lost, or is this still an effect of those initial what was it, 5 or 7 contracts that you lost earlier in 2025 that in a way should be out of comps soon? If I could do a follow-up to the follow-up, how much of the -11% organic growth that you saw in UK was from the rental part of the business versus the product side?

Christofer Carlsson
37:04 - 37:23

When it comes to the rental business in general in the UK, we have not lost any new contracts in the quarter, so it is more an effect of the early ones that we communicated in 2025. And then I have to come back to you on the rental margins for UK.

Andréas Elgaard
37:25 - 37:39

How do we usually communicate them? So I think that if we don't communicate them, we will probably not come back. But if we do that, then we'll come back to you. Just to be clear.

Eric Castle
37:40 - 38:08

So I'm just wondering in terms of those pruning, additional costs, etc., how much are you actually able to slim the organization from this point? I'll wait and see you then. Yes. And then just a final question. There's been a hiring freeze now, outside of sales for quite some time, I believe. So I'm just wondering in terms of those pruning, additional costs, etc. How much are you actually able to slim the organization from this point? It seems like this sort of pruning has been done for years now. So are you nearing a point where you can't really cut any more fat?

Andréas Elgaard
38:10 - 39:52

I don't think I would express myself in that way about the organization, but we can see that, as any organization, we have room to improve. And we are going to focus on that. And part of that will, of course, be related to improving our profitability. And part of that might also be funding the journey of investing in creating a strong future. Arjo. So, Christofer can add some flavor, but I have now three and a half weeks in the company. I've spent some time during my onboarding as well, but the only thing I can share is that I see opportunity across ARJO. It's a really mature business, but we also have some inefficiencies. We don't always use our best practice. We don't always share our failures or our successes across the company. And there's a lot of commercial excellence in that. And if we can release that, that has a really positive effect. I have firsthand experience of doing that in other contexts. And then also, we need to take a good look in the mirror and put question marks to ourselves when it comes to our administrative costs. Because we are high and we need to be able to do things more efficiently by leveraging our IT systems and by also delivering the administration that is necessary and not something beyond that. So there are clear opportunities for us to address. Then it is too early to say when the effect will come and so on. But we will focus on this together as an organization.

Eric Castle
39:55 - 39:57

I don't think I would express myself in that way about the organization, but we can see that, as any organization, we have room to improve. I don't think I would express myself in that way about the organization, but we can see that, as any organization, we have room to improve.

Operator
40:00 - 40:04

The next question comes from Ludvig Lundgren from Nordea. So, Christopher can add some flavor, but I have now three and a half weeks in the company.

Ludvig Lundgren
40:06 - 40:24

I don't think I would express myself in that way about the organization, but we can see that we have, as any organization, room to improve. Hi and thank you for taking my question. I only have one. So you have highlighted quite strong order intake in the last few quarters, in particular in patient handling products in the US. So can you say anything about how this has developed here in Q4 and whether you're still way above one in book to bill?

Christofer Carlsson
40:26 - 40:45

Yes, the order intake has come in a little bit weaker in the quarter. But from the order book perspective, we are almost at the same level as last year. Slightly better.

Ludvig Lundgren
40:45 - 40:45

Thank you very much.

Christofer Carlsson
40:46 - 41:01

But also, please remind yourself that 80% of our transaction is in and out in the same period. So it's an indicator, but it's not the actual truth of the sales in the coming quarters.

Ludvig Lundgren
41:03 - 41:04

Understood.

Operator
41:09 - 41:28

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Andréas Elgaard
41:30 - 41:56

So by that, we close this call, the year-end report for 2025. I thank you for listening. I also thank you for bearing with me as I am new, and I am really looking forward to coming back and presenting Q1 to you, and in the second half, presenting our future strategy. By that we say thank you.

Christofer Carlsson
41:57 - 41:57

Thank you all.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…